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 ABSTRACT 
 
Background: A major threat to the validity of longitudinal cohort studies is non-response to follow-
up, which can lead to erroneous conclusions. The profile of chronic diseases non-respondents is 
therefore important, but has rarely been assessed. The objective of this study was to evaluate the 
number and profile of non-respondents to the self-reported questionnaires among patients included 
in the Swiss Inflammatory Bowel Disease Cohort (SIBDC).  
Methods: In this study, we included all patients enrolled between 1st November 2006 and 30th June 
2011. Patients who returned the questionnaires and those who did not were compared using age, 
sex, and various disease and socio-demographic characteristics. 
Results: Among 1945 IBD patients who received the inclusion questionnaire 340 (17.2%) did not 
respond (18.8% CD, 15.6% UC). Risks factors of non-response for patients with CD were: older 
age, male gender, shorter disease duration and complicated disease behaviour, whereas only shorter 
disease duration was significant for UC patients. Out of 1605 patients who received the first follow-
up patient questionnaire 323 (24%) did not respond (26% CD, 21.4% UC). The CD non-
respondents had lower level of education, ileal disease location, lower number of surgery and use of 
immunomodulators or biologicals and lower IBDQ while UC non-respondents were single, had 
active disease, less resection surgery and not currently receiving immunomodulator or biological 
therapies. 
Conclusions: In conclusion, assessing non-respondents’ characteristics are necessary to develop 
strategies to minimize non-response in future studies. 
 KEYWORDS 
Crohn’s disease, ulcerative colitis, non-respondent, self-administrated questionnaires, bias, 
epidemiological study 
 
 INTRODUCTION 
Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC). These 
are chronic inflammatory diseases of the gastrointestinal tract of unknown aetiology characterized 
by alternating periods of remission and relapse. Often diagnosed in adolescence, these diseases have 
considerable impact on patients’ daily life including recurrent physical symptoms, psychosomatic 
distress and poorer social and professional functioning1, 2. IBD is considered as a disease of 
industrialized nations, and is rising in societies with increasing western life-styles3-5. The incidence 
of IBD has stabilised since the end of the 20th century in high-incidence areas but prevalence is still 
increasing, due to the longer life expectancy of patients with these diseases3-5. Many countries 
have now started cohort studies involving IBD patients to observe disease course and its burden 
over time and to get up-to-date epidemiological data3, 4, 6.  
A major threat to the validity of longitudinal cohort studies is non-response to follow-up, which can 
lead to erroneous conclusions. Follow-up non-response is however inevitable and the scope to 
which it could bias study results is of major concern7-9. Attrition rates in epidemiologic studies 
have increased significantly over the past 30 years10. Among factors related to non-participation 
over time is the increasing rate of men and women having full-time employment and thus less time 
for study participation and complex survey instruments involving medical assessments, biologic 
sampling, and repetitive requests for follow-up that are sometimes burdensome for participants10-
12. Data on participation rates are rarely discussed in cohort studies of IBD. In the Manitoba Cohort 
Study an attrition rate of 9% was reported after two years of follow-up13. In studies of other 
chronic inflammatory disease like rheumatoid arthritis14, the non-response rate to the first study 
questionnaire was as high as 31%. Health surveys in Europe usually reported a 10-30% non-
response rate13, 15.  
The Swiss IBD Cohort Study (SIBDCS) started in 2006 with the objective to provide up-to-date 
epidemiological data and to investigate risk factors associated with the course of the disease16. This 
cohort includes prevalent and incident IBD patients, with a yearly follow-up.  The goal of the 
 present study is to document socio-demographic, clinical and/or psychosocial factors associated 
with non-response to patient initial and first follow-up self-reported questionnaires to define profiles 
of non-respondents to be taken into account in further studies performed with those cohort data.  
 
 MATERIALS AND METHODS 
Study design and population 
We used data from the Swiss IBD Cohort, which started on 1st November 2006. Participants were 
recruited through their gastroenterologist. A requirement for inclusion was residing permanently in 
Switzerland or having contracted Swiss health insurance and being treated on a regular basis in 
Switzerland. Diagnosis had to be established at least 4 months prior to inclusion or after at least one 
recurrence of the symptoms. Diagnosis was assessed using Lennard-Jones criteria, and was 
confirmed by radiological, endoscopic and histological findings. In this study, we included all 
patients enrolled between 1st November 2006 and 30th June 2011, at which time all of them received 
at least 2 reminders to complete their first follow-up self-administrated questionnaire, i.e., by the 
end of June 2013. We excluded paediatric patients and those with indeterminate colitis.  
Data collection and management 
Following a screening procedure, to confirm that patients met the inclusion criteria and provided 
informed consent, patients were enrolled by the gastroenterologist who then completed an initial 
medical questionnaire (IMQ). Patients were subsequently invited to complete an initial patient 
questionnaire (IPQ). After one year, patients had an annual medical examination with their treating 
gastroenterologist to update their medical record. During the visit the physician / study nurse 
completed a follow-up medical questionnaire (FMQ). In addition, an annual follow-up patient 
questionnaire (FPQ) was sent to the patient to update the psychosocial, habits and health resource 
consumption evolution. Non-respondents to IPQ and FPQ were sent a first reminder 3 months after 
the first sending, followed by a second one at 12 months. We preformed two analysis, one 
investigating responses to IPQ and the other responses to FPQ. Patients selected for each analysis 
are described in the Figure 1. It is important to take account to the fact that patients who completed 
FPQ are an extract of those who already completed IPQ. If a patient did not complete IPQ, he never 
received FPQ. 
 Outcome and exposures 
We considered two outcomes: the first was non-response to the IPQ and the second was non-
response to the FPQ. Risk factors that were taken into account were: age, sex, age at diagnosis, 
disease duration, history of surgery (none, resection surgery, surgery for fistula or abscess, other 
abdominal surgery) and current therapies (none, 5-ASA compounds, systemic steroids, 
immunomodulators, biological). Therapies and surgeries were considered as binary variables, not 
unordered categorical because one patient could have had multiple therapies or surgeries. For 
patients affected by CD, we considered disease location (ileal, colonic, ileocolonic, upper 
gastrointestinal involvement) and severity (Crohn's disease activity index - CDAI) as measured 
during the medical visits. This latter variable was considered as categorical with categories: active 
(CDAI>=150) and remission (CDAI<150). Disease behaviour was based on Montreal classification 
(non stricturing non penetrating, stricturing, penetrating, perianal disease modifier). For patients 
with UC, we considered disease location (proctitis, left-sided colitis, pancolitis) and severity 
(Modified Truelove and Witts activity index (MTWAI)) with 2 categories: active (MTWAI>=3) and 
remission (MTWAI<3). These variables were based on data from the IMQ for the primary analysis 
and from the IMQ or FMQ for the secondary analysis. Socio-demographic variables were marital 
status (married versus single), educational level (none or compulsory education, upper secondary 
education, tertiary education) and social support as assessed by the ENRICHD Social Support 
Inventory Scale, which is a 7-item score that measures emotional, practical and informational 
support. Quality of life (Qol) was evaluated through the SF36 questionnaire, which assessed 8 
health domains (Physical Functioning, Physical Role, Emotional Role, Vitality, Mental Health, 
Social Functioning, Bodily Pain, General Health Perception) that contribute each in a different 
proportion to the scoring of the Physical Component Summary and the Mental Component 
Summary and the Inflammatory Bowel Diseases Questionnaire (IBDQ) (32 items, 4 sub-scores: 
bowel symptoms, systemic symptoms, emotional function and social function). Mood was assessed 
with the Hospital Anxiety and Depression Scale (HADS) divided in 2 sub-scales, one assessing 
 depression and the other anxiety. A score of 0 to 7 is considered normal, 8 to 10 mild, 11 to 14 
moderate and 15 to 21 severe anxiety or depression. 
Clinical variables considered for each patient were those referring to the closest medical visit, i.e. 
for the analysis of patients non-respondent to IPQ we consider clinical variables collected in the 
IMQ; for the analysis of patients non-respondent to FPQ we used data from the last medical 
questionnaire available and preceding the FPQ: FMQ or IMQ.  
Statistical analysis 
Descriptive statistics were conducted to compare baseline characteristics of respondent vs. non-
respondent to the IPQ and respondent vs. non-respondent to the FPQ; in both groups, two-sample t-
tests were used to compare means of normally distributed variables or Wilcoxon rank-sum test to 
compare distribution of non-normally distributed variables. Chi-square tests were used to test the 
null hypothesis of no association between groups for categorical and binary variables.  
To explore risk factors explaining no-response to questionnaires, we first performed univariate 
logistic regression. Multivariate logistic regression was performed first with all covariates with a 
univariate p-value < 0.2, removing insignificant covariates, and then adding remaining covariates 
one by one, checking the model significance and consistency at each step. For the purposes of this 
study, a p-value of < 0.05 was considered statistically significant. We performed separate analyses 
for CD and UC because disease phenotypes are not comparable. All analyses were performed on the 
set of data without missing values. Statistical analyses were conducted using Stata Version 12 
(StataCorp LP, College Station, TX, USA). 
 RESULTS 
Responders and non-responders to IPQ 
On the 30th of June 2011 a total of 1979 patients were included in the SIBDC; 34 of those contained 
a missing value and where excluded from analyses. Among the 1945 patients included in the first 
analysis, figure 1, 1130 had CD (58%) and 815 had UC (41%). Non-responders were slightly more 
frequent in CD (N=213, 18.8%), table 1, than in UC (N=127, 15.6%), table 2. Younger CD patients 
tend to respond less than older patients (37 vs. 42 years old; p<0.001). The proportion of females 
who responded to IPQ was higher than males (p<0.05) for CD, whereas no difference was observed 
among patients with UC. For both CD and UC patients, non-responders had a shorter disease 
duration (6 vs. 9 years for CD, p<0.001 ; 6 vs. 7 years for UC, p<0.05). CD disease behaviour was 
associated with response to IPQ, indeed non-responders more frequently had a complicated disease 
presentation (with stenosis, fistula) than responders. Non-responders with CD had a higher 
proportion of perianal involvement than responders (18.0% vs. 29.1%; p<0.001). No association 
between disease activity and response to IPQ was observed and around two-third of patients with 
CD or UC were in remission at enrolment. There were no statistical differences about therapies for 
CD neither for UC, but it is interesting to notice that nearly forty-five percent of CD patients 
received an immunomodulator and one quarter a biological therapy at the time of inclusion and 
two-thirds of UC patients were receiving 5-ASA. 
Predictors of non-response to IPQ 
We performed multivariate regression to find the most appropriate set of independent risk factors 
for being non-respondent to IPQ, table 3. After adjustment, we found that CD and UC profiles for 
being non-respondent to IPQ was different. The odds of having a longer disease duration is 1.03 
times greater for responders as compared to non-responders, in CD (p=0.003) and in UC (p=0.014). 
In CD only, being a female (OR=1.48; 95%CI: 1.09-2.02) and having a higher age at inclusion 
(OR=1.01; p=0.011) are independent factors for being a responder to IPQ. On the opposite, having 
a stricturing vs. penetrating disease behaviour decreased the odds of being responder to IPQ by 
 approximately 40% vs. 60%. 
 
Responders and non-responders to FPQ 
Among the 1945 patients included in the first analysis, 1605 responded to the IPQ. To be able to 
perform univariate and multivariate analyses of response to FPQ on the same sample of patients, we 
selected patients for whom variables used for analyses were not missing. The total number of 
patients that were thus selected was 1346, figure 1, 771 with CD and 575 with UC. Nearly one 
quarter of CD patients (N=200), and one fifth of UC patients (N=123) did not respond to FPQ. The 
proportion of female non-responders to FPQ was not significantly different from responders to 
FPQ; however they were more frequent than non-responders to IPQ (60.5% vs. 45.5%), table 1. CD 
non-responders were younger (38 vs.42 years old; p<0.05) and had a shorter disease duration (6 vs. 
9 years; p<0.05). The proportion of CD patients with active disease was higher among non-
responders to FPQ (69.5% vs. 78.5%; p<0.05). As observed in the first analysis, patients with more 
complicated disease behaviour, or a perianal involvement were also more frequently non-
respondent to FPQ. Non-responders had less previous resection surgery than responders, in CD 
(32.5% vs. 41.2%; p<0.05) or in UC (2.4% vs. 8.6%, p<0.05). In overall, patients who did not reply 
to FPQ were less frequently receiving a drug treatment; not being under biological therapy in CD or 
immunomodulator therapy in UC was significantly associated with non-response to FPQ. 
The proportion of patients being married was significantly lower in non-responders (34.5% for CD, 
46.3%), table 3, compared to responders. Lower education level was associated with non-response 
to FPQ, but only in CD. Patients who did not respond to FPQ had a lower positive social support 
than responders. Around 10% more non-responders CD patients had mild to severe depression, as 
well as significantly lower mental health SF-36 components scales and IBDQ scores. No other 
psychosocial factors differed between responders and non-responders in UC.  
Predictors of non-response to FPQ 
We performed multivariate regression to find independent risk factors for being non-respondent to 
 FPQ, table 5. We found a completely different profile for being non-respondent to FPQ among CD 
and UC. The odds of having a longer disease duration is 1.03 times greater for responders as 
compared to non-responders, in CD only  (p=0.003) but not in UC. In CD having a disease located 
in the upper GI or the colon, a history of resection surgery (OR=1.64; 95%CI: 1.05-2.55) or surgery 
for fistula (OR=2.09; 95%CI: 1.21-3.61), being under immunomodulator (OR=1.69; p=0.004) or 
biological therapy (OR=2.18; p<0.001) remained independent factors for being a responder to FPQ. 
Risk factors associated to both of these treatments were also observed for UC. On the opposite, 
having a stricturing vs. penetrating disease behaviour decreased the odds of being responder to FPQ 
by approximately 60% vs. 70%. Patients with at least upper 2nd education were significantly more 
responders to FPQ. Other independent risk factors for being responder to FPQ in UC were non-
active disease, history of surgery and marital status (OR=1.85; p=0.004). 
 
 
 
 
 
 
 DISCUSSION 
This paper reports a detailed analysis of risk factors associated with non-response to IPQ and FPQ 
in the Swiss IBD Cohort Study. The results show differences between respondents and non-
respondents and between IPQ and FPQ respondents and different profiles according to diagnostic. 
Age, female gender, disease duration and non-complicated disease behaviour were independent risk 
factors for response to IPQ among patients with CD, whereas education, disease location, history of 
surgery and current use of immunosuppressants or biologicals and higher IBDQ were additional 
risk factors for response of CD to FPQ. UC patients with longer disease duration were at higher risk 
of response to IPQ, and married UC patients, in remission, having had resection surgery, and 
currently receiving immunomodulator or biological therapy were at higher risk of response to FPQ. 
 
Prior studies have found that follow-up responders tend to differ from non-responders in their 
sociodemographic and health characteristics. Short disease duration, young age and male gender 
have already been found as risks factors of non-response in some studies. We can make the 
assumption that patients not having a long standing illness are younger and young age implies 
higher risks behaviours, increased individualism and lower willingness to follow authority 
especially among young men7, 11, 15 17. Furthermore, if the disease is relatively new, maybe the 
impact to the life of the patient is not perceived as hard as if it was present and impeding for years. 
Indeed, when the study investigate a particular symptom or condition that someone has, he could 
feel deeper involved and be more likely to participate in.  11, 14, 15.  However, it is interesting to 
notice that the difference in term of disease duration is not very high. It would be useful to stratify 
non-response with various categories of disease duration (1-2 years vs 2-5 vs 5-10…) to see if it has 
a connexion with the stages of accepting the illness. Indeed, this small difference could be 
explained by the denial and isolation phase that characterise the beginning of the disease and could 
no longer be present after a few years. 
Concerning disease characteristics, our findings match with studies reporting higher morbidity and 
 health care utilization among respondents. Again, the relevance of the study to the life of 
participants provides special motivation for participation1114, 15, 18. For patients with CD, it is 
reported that non-respondents have their lesions located more in the ileal part of the bowel. Prior 
studies did not search for such a connection between nonresponse and disease location, or did not 
find one19. However, Vind et al. mention that older patients had more colonic location, younger 
patients had more ileal location and ileal location has more structuring and penetrating behaviour3, 
which could fit with our results wherein non-responders have shorter disease duration, more 
complicated behaviour and ileal location.  
The socio-demographic characteristics of non-responders in the SIBDCS are consistent with 
previous studies saying that patients with lower education level, mood disorders, greater levels of 
psychological and disease-related difficulties, lower SF-36, being unmarried, less socially active, 
having reduced physical function, mental health and less positive health-related behaviours are 
associated with greater level of non-response2, 7, 13, 17, 18, 20, 21. It has been demonstrated in 
patients with ischemic heart disease that lack of social support is associated with increasing 
morbidity22. It has been demonstrated 23 that higher social support in IBD patients enhance 
positive thoughts and increase the faculty to face and deal with stress and life difficulties. These 
results imply that patients who are the most in need of psychological and social help may not be 
reached. Future researchers have to increase effort and resources into encouraging participation for 
patients with these characteristics in order to reduce non-response and assist the most vulnerable 
patients.  
The strengths of this study include the large sample size, the sample selection technique that allow a 
great diversity of patients (geographically and demographically), the use of not only traditional 
socio-demographic characteristics but also medical treatment, disease extent and clinical 
characteristics, diversity of data collection means (medical visits and patients questionnaires) and 
the use of validated indices. 
There are several limitations that should be considered when interpreting our results. First, we 
 treated all non-respondents as a homogeneous group and did not differentiate whether patients did 
not respond due to refusal or inability to be contacted. Second, in the secondary analysis we have 
more medical information over time about respondents as they have had more medical visits so it 
can create false differences because of the information gap. Third, in the second analysis, we do not 
include the IPQ non-responders and it could potentially bias the results. 
 
In conclusion, we found that young age, male gender, short disease duration, few therapies or 
surgeries, severe disease, low quality of life and not being married can be risks factors for non-
response. One hypothesis could be that patients with less social support live their disease more 
heavily and are less encouraged to fight against it, which results in lower quality of life, less 
medical monitoring or compliance and therefore more severe disease. Assessing non-respondents’ 
characteristics is necessary to develop strategies to minimize non-response in future studies 
(increase financial insensitive, increase number and methods of contacts…). Great efforts need to 
be made to motivate response from all patients (with a certain type of disease, with severe or less 
severe disease, with more or less health care utilization,... ) to have the most representative sample 
possible so non-response does not affect the validity of study results.  
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 TABLES AND FIGURES 
Figure 1: flow chart for the selection of patients included in the two analyses performed: (A) 
respondent to initial patient questionnaires (IPQ); (B): respondents to follow-up questionnaires 
(FPQ). 
 
 
 
 
 
 
 
 
 Table 1: clinical characteristics of CD patients at enrolment visit and at the first follow-up visit. 
Values are numbers and percentages unless stated otherwise. 
 
Variable Enrolment 
(N=1130) 
Follow-up (N=771) 
Variable Responders 
N=917 (81.2)
Non-responders
N=213 (18.8) 
Responders 
N=571 (74.0) 
Non-responders
N=200 (26.0) 
Age (years)$ 42 (15) 37 (14)** 42 (14) 38 (15)* 
Female Gender 501 (54.6) 97 (45.5)* 315 (55.2) 121 (60.5) 
Age at diagnosis (years) £ 26 (17) 25 (16) 26 (17) 25 (17.5) 
Disease duration (years) £ 9 (14) 6 (10)** 9 (14) 6 (11 * 
Disease activity    * 
Remission (CDAI < 150) 584(63.7) 137 (64.3) 448 (78.5) 139 (69.5) 
Active (CDAI > 150) 333 (36.3) 76 (35.7) 123 (21.5) 61 (30.5) 
Disease location     * 
Ileal only 276 (30.1) 61 (28.6) 148 (25.9) 66 (33.0) 
Colonic 346 (37.7) 81 (38.0) 231 (40.5) 57 (28.2) 
Ileocolonic 285 (31.1) 70 (32.9) 158 (27.7) 67 (33.5) 
Upper GI involvement only 10 (1.1) 1 (0.5) 34 (6.0) 10 (5.0) 
Behaviour   **  ** 
Non stricturing, non penetrating 647 (70.6) 121 (56.8) 430 (75.3) 119 (59.5) 
Stricturing 159 (17.3) 43 (20.2) 84 (14.7) 47 (23.5) 
Penetrating 111 (12.1) 49 (23.0) 57 (10.0) 34 (17.0) 
Perianal involvement 1665 (18.0) 62 (29.1)** 79 (13.8) 58 (29.0)** 
History of surgery     
None  429 (46.8) 112 (52.6) 257 (45.0) 99 (49.5) 
Previous resection surgery 353 (38.5) 69 (32.4) 235 (41.2) 65 (32.5)* 
Previous surgery for fistula or abscess 197 (21.5) 45 (21.1) 135 (23.6) 38 (19.0) 
Current therapy     
None 107 (11.7) 23 (10.8) 48 (8.4) 23 (11.5) 
5-ASA compounds 171 (18.7) 31 (14.5) 116 (20.3) 37 (18.5) 
Systemic steroids 178 (19.4) 50 (23.5) 127 (22.2) 43 (21.5) 
Immunomodulators 431 (47.0) 96 (45.1) 307 (53.8) 93 (46.5) 
Biological therapy 227 (24.7) 63 (29.6) 191 (33.4) 51 (25.5)* 
$mean (SD); £median (IQR); **p<0.001; *p<0.05; indication of p-values for chi2 testing between categorical 
variables are put in the corresponding subheading line 
 
 
 Table 2: clinical characteristics of UC patients at enrolment visit and at the first follow-up visit. 
Values are numbers and percentages unless stated otherwise. 
 
Variable Enrolment (N=815) Follow-up (N=575) 
Variable Responders 
N=688 (84.4)
Non-responders 
N=127 (15.6) 
Responders 
N=452 (78.6) 
Non-responders
N=123 (21.4) 
Age (years)$ 43 (15) 41 (13) 43 (14) 41 (14) 
Female Gender 372 (45.6) 266 (46.3) 215 (47.6) 51 (41.5) 
Age at diagnosis (years) £ 31 (17) 32 (16) 31 (17) 30 (16) 
Disease duration (years) £ 7 (12) 6 (10)* 7 (12) 5 (12) 
Disease activity     
Remission (MTWAI < 3) 455 (66.1)  76 (59.8) 330 (73.0)  80 (65.0) 
Active (MTWAI > 3) 233 (33.9) 51 (40.2) 122 (27.0) 43 (35.0) 
Disease location      
Proctitis 110 (16.0) 14 (11.0) 78 (17.3) 22 (17.9) 
Left-sided colitis 292 (42.4) 53 (41.7) 194 (42.9) 50 (40.7) 
Pancolitis 286 (41.6) 60 (47.2) 180 (39.8) 51 (41.5) 
History of surgery     
None 612 (89.0) 113 (89.0) 392 (86.7) 110 (89.4) 
Previous resection surgery 41 (6.0) 6 (4.7) 39 (8.6) 3 (2.4)* 
Previous surgery for fistula or abscess 15 (2.2) 3 (2.2) 10 (2.2) 4 (3.2) 
Current therapy     
None 75 (9.4) 10 (7.9) 34 (7.5) 13 (10.6) 
5-ASA compounds 422 (61.3) 82 (64.6) 300 (66.4) 80 (65.0) 
Systemic +/- topic steroids 176 (25.6) 31 (24.4) 131 (29.0) 30 (24.4) 
Immunomodulators 215 (31.2) 42 (33.1) 175 (38.7) 29 (23.6)* 
Biological therapy 54 (7.8) 11 (8.7) 54 (11.9) 9 (7.3) 
$mean (SD); £median (IQR); *p<0.05; indication of p-values for chi2 testing between categorical variables 
are put in the corresponding subheading line 
 
 
 
 
 
 Table 3: patient self-reported characteristics of CD and UC patients who replied to FPQ. Values are 
numbers and percentages unless stated otherwise. 
 Variable CD UC 
 Variable Responders
N=571 
Non-responders
N=200 
Responders 
N=452 
Non-responders
N=123 
Married  265 (46.4) 69 (34.5)* 268 (59.3) 57 (46.3)* 
Education level  *   
  None or compulsory 57 (10.0) 37 (18.5) 43 (9.5) 14 (11.4) 
  Upper 2nd education  340 (59.5) 117 (58.5) 260 (57.5) 56 (45.5) 
  Tertiary education  174 (30.5) 46 (23.0) 149 (33.0) 53 (43.1) 
Anxiety     
  No anxiety 346 (60.6) 107 (53.5) 307 (67.9) 74 (60.2) 
  Mild 127 (22.2) 46 (23.0) 83 (18.4) 29 (23.6) 
  Moderate 77 (13.5) 36 (18.0) 48 (10.6) 14 (11.4) 
  Severe 21 (6.7) 11 (5.5) 14 (3.1) 6 (4.9) 
Depression  *   
  No depression 472 (82.7) 148 (74.0) 371 (82.1) 99 (80.5) 
  Mild 55 (9.6) 30 (15.0) 55 (12.2) 15 (12.2) 
  Moderate 39 (6.8) 18 (9.0) 21 (4.7) 6 (4.9) 
  Severe 5 (0.9) 4 (2.0) 5 (1.1) 3 (2.4) 
Positive social support$ 25.3 (5.3) 24.3 (6.0)* 25.8 (5.2) 24.3 (5.9)* 
SF-36 Physical Functioning (PF)$ 84.0 (20.6) 82.6 (20.3) 87.0 (18.8) 86.4 (18.6) 
SF-36 Physical role (PR)$ 68.3 (39.5) 64.1 (40.2) 70.3 (39.4) 73.6 (36.3) 
SF-36 Emotional role (ER)$ 73.9 (38.2) 66.8 (39.5)* 78.5 (34.9) 77.0 (35.2) 
SF-36 Vitality (V)$ 49.0 (21.8) 44.7 (23.4)* 50.0 (20.2) 51.1 (21.0) 
SF-36 Mental Health (MH)$ 65.0 (19.5) 60.8 (21.1)* 66.8 (18.0) 64.9 (20.4) 
SF-36 Social Functioning (SF)$ 72.6 (26.6) 66.3 (28.6)* 75.9 (25.7) 75.78 (23.7) 
SF-36 Bodily Pain (BP)$ 66.5 (27.4) 62.3 (28.4) 71.4 (26.4) 70.1 (26.5) 
SF-36 General Health Perceptions (GHP)$ 55.1 (22.5) 51.9 (22.5) 58.9 (20.9) 57.4 (21.3) 
SF-36 Physical component summary (PS)$ 46.7 (10.0) 46.0 (10.3) 48.2 (9.3) 48.4 (9.1) 
SF-36 Mental component summary (MS)$ 44.7 (11.6) 41.9 (12.2)* 45.7 (9.9) 45.1 (11.1) 
IBDQ Bowel Symptoms score$ 56.1 (10.1) 54.0 (11.0)* 57.0 (11.1) 56.1 (11.7) 
IBDQ Emotional Function score$ 24.2 (6.1) 22.7 (6.5)** 24.8 (5.9) 24.2 (6.2) 
IBDQ Social Function score$ 64.3 (12.7) 60.8 (13.9)* 65.2 (12.4) 64.0 (13.7) 
IBDQ Systemic Symptoms score$ 29.9 (6.2) 28.7 (7.0)* 30.0 (7.0) 30.7 (6.1) 
IBDQ total score$ 174.5 (31.1) 166.1 (34.6)* 177.1 (32.9) 175.0 (33.6) 
$mean (SD); SF-36 values in the general population: PF: 82.5 (22.9); PR: 81.2 (33.8); ER: 81.3 (33.0); V: 
61.0 (20.9); MH: 74.8 (18.0); SF: 83.6 (22.4); BP: 75.5 (23.6); GHP: 72.2 (20.2); PS and MS: 50 (19) ; 
*p<0.05; **p<0.001; indication of p-values for chi2 testing between categorical variables are put in the 
corresponding subheading line 
 Table 4: Multivariate analysis for risk factors associated to response to IPQ for patient with CD and 
UC 
  
Variable OR (95% CI) for 
response among 
CD 
P-value OR (95% CI) for 
response among 
UC 
P-value 
Female gender 1.48 (1.09-2.02) 0.011   
Age at inclusion 1.01 (1.00-1.02) 0.011   
Disease duration 1.03 (1.01-1.05) 0.003 1.03 (1.00-1.05) 0.014 
Stricturing disease behaviour 0.61  (0.41-0.91) 0.017   
Penetrating disease behaviour 0.34 (0.22-0.51) <0.001   
 
 
 
 Table 5: Multivariate analysis for risk factors associated to response to FPQ for patient with CD 
and UC 
  
Variable OR (95% CI) for 
response among 
CD 
P-value OR (95% CI) for 
response among 
UC 
P-value 
Disease duration 1.03 (1.01-1.05) 0.003   
Active disease   0.57 (0.36-0.91) 0.019 
Colonic only disease location 1.98 (1.26-3.11) 0.003   
Ileocolonic disease location 1.04 (0.66-1.63) 0.856   
Upper GI disease location 1.54 (0.67-3.55) 0.303   
Stricturing disease behaviour 0.41 (0.26-0.67) <0.001   
Penetrating disease behaviour 0.30 (0.17-0.54) <0.001   
Perianal involvement 0.27 (0.16-0.44) <0.001   
History of resection surgery 1.64 (1.05-2.55) 0.028 5.54 (1.62-18.8) 0.006 
History of Fistula/abscess surgery 2.09 (1.21-3.61) 0.008   
Current immunomodulator therapy 1.69 (1.17-2.43) 0.004 2.31 (1.44-3.70) <0.001 
Current biological therapy 2.18 (1.43-3.31) <0.001 2.29 (1.06-4.95) 0.035 
Marital status   1.85 (1.22-2.82) 0.004 
Upper 2nd education  2.00 (1.20-3.33) 0.008   
Tertiary education  2.29 (1.28-4.07) 0.005   
IBDQ total 1.00 (1.00-1.01) 0.001   
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 SUPPLEMENTARY TABLES 
 
Table 1: Crude odds ratios (OR) and 95% confidence intervals (CI) for response to IPQ and FPQ 
according to clinical characteristics of CD patients.  
 
Variable OR (95% CI) for 
response to IPQ  
P-value OR (95% CI) for 
response to FPQ 
P-value 
Age 1.02 (1.01-1.03) <0.001 1.01 (1.00-1.03) 0.011 
Female Gender 1.44 (1.07-1.94) 0.017 0.80 (0.58-1.11) 0.191 
Age at diagnosis 1.01 (1.00-1.02) 0.080 1.00 (0.99-1.01) 0.733 
Disease duration 1.03 (1.01-1.05) <0.001 1.03 (1.01-1.05) 0.001 
Disease activity     
Remission (CDAI < 150) 1.00  1.00  
Active (CDAI > 150) 1.03 (0.75-1.40) 0.862 0.62 (0.43-0.90) 0.011 
Disease location      
Ileal only 1.00  1.00  
Colonic 0.94 (0.65-1.36) 0.759 1.81 (1.20-2.72) 0.005 
Ileocolonic 0.90 (0.61-1.38) 0.587 1.05 (0.70-1.58) 0.809 
Upper GI involvement only 2.21 (0.28-17.6) 0.454 1.52 (0.71-3.25) 0.285 
Behaviour      
Non stricturing, non penetrating 1.00  1.00  
Stricturing 0.69 (0.47-1.02) 0.063 0.49 (0.33-0.74) 0.001 
Penetrating 0.42 (0.29-0.62) <0.001 0.46 (0.29-0.74) 0.001 
Perianal involvement 0.53 (0.38-0.75) <0.001 0.39 (0.27-0.58) <0.001 
History of surgery     
None 0.79 (0.59-1.07) 0.127 0.83 (0.60-1.15) 0.273 
Previous resection surgery 1.31 (0.95-1.79) 0.098 1.45 (1.03-2.04) 0.031 
Previous surgery for fistula or abscess 1.02 (0.71-1.47) 0.909 1.32 (0.88-1.97) 0.176 
Current therapy     
None 1.09 (0.68-1.76) 0.720 0.71 (0.42-1.19) 0.195 
5-ASA compounds 1.34 (0.89-2.04) 0.161 1.12 (0.74-1.69) 0.580 
Systemic steroids 078 (0.55-1.21) 0.184 1.04 (0.71-1.54) 0.828 
Immunomodulators 1.08 (0.80-1.46) 0.611 1.34 (0.97-1.85) 0.077 
Biological therapy 0.78 (0.56-1.09) 0.147 1.47 (1.02-2.11) 0.038 
 
 
 Table 2: Crude odds ratios (OR) and 95% confidence intervals (CI) for response to IPQ and FPQ 
according to clinical characteristics of UC patients.  
 
Variable OR (95% CI) for 
response to IPQ  
P-value OR (95% CI) for 
response to FPQ 
P-value 
Age 1.01 (0.99-1.02) 0.140 1.01 (0.99-1.02) 0.176 
Female Gender 1.35 (0.92-1.99) 0.123 1.28 (0.85-1.91) 0.229 
Age at diagnosis 1.00 (0.98-1.01) 0.964 1.00 (0.99-1.02) 0.228 
Disease duration 1.03 (1.00-1.05) 0.014 1.00 (0.97-1.02) 0.755 
Disease activity     
Remission (MTWAI < 3) 1.00  1.00  
Active (MTWAI > 3) 0.76 (0.51-1.12) 0.172 0.68 (0.44-1.05) 0.084 
Disease location      
Proctitis 1.64 (0.88-3.07) 0.115 1.09 (0.70-1.70) 0.673 
Left-sided colitis 1.15 (0.77-1.73) 0.482 1.00 (0.57-1.76) 0.987 
Pancolitis 1.00  1.00  
History of surgery     
None 0.99 (0.54-1.8) 0.994 0.77 (0.40-1.45) 0.425 
Previous resection surgery 1.27 (0.53-3.07) 0.584 3.77 (1.14-12.43) 0.029 
Previous surgery for fistula or abscess 0.92 (0.26-3.22) 0.898 067 (0.20-2.18) 0.510 
Current therapy     
None 1.22 (0.60-2.44) 0.574 0.68 (0.35-1.34) 0.276 
5-ASA compounds 0.87 (0.58-1.29) 0.491 1.06 (0.69-1.61) 0.782 
Systemic +/- topic steroids 1.06 (0.68-1.65) 0.780 1.26 (0.79-2.00) 0.315 
Immunomodulators 0.91 (0.61-1.37) 0.685 2.04 (1.29-3.25) 0.002 
Biological therapy 0.89 (0.45-1.76) 0.756 1.71 (0.82-3.58) 0.149 
 
 
 
 Table 3: Crude odds ratios (OR) and 95% confidence intervals (CI) for response to FPQ according 
to patient self-reported characteristics of CD and UC patients.  
 
Variable OR (95% CI) for 
response to FPQ 
among CD 
P-value OR (95% CI) for 
response to FPQ 
among UC 
P-value 
Education level     
  None or compulsory 1.00  1.00  
  Upper 2nd education  1.88 (1.85-3.00) 0.007 1.51 (0.77-2.95) 0.226 
  Tertiary education  2.45 (1.45-4.15) 0.001 0.91 (0.46-1.80) 0.799 
Married  1.64 (1.17-2.29) 0.004 1.68 (1.12-2.51) 0.011 
Anxiety     
  No anxiety 1.00  1.00  
  Mild 0.85 (0.57-1.27) 0.440 0.68 (0.42-1.12) 0.140 
  Moderate 0.66 (0.42-1.03) 0.073 0.82 (0.43-1.57) 0.564 
  Severe 0.59 (0.27-1.26) 0.175 0.56 (0.20-1.51) 0.254 
Depression     
  No depression 1.00  1.00  
  Mild 0.57 (0.35-0.93) 0.024 0.97 (0.53-1.80) 0.944 
  Moderate 0.67 (0.37-1.22) 0.198 0.93 (0.36-2.37) 0.886 
  Severe 0.39 (0.10-1.47) 0.167 0.44 (0.10-1.89) 0.273 
Positive social support$ 1.03 (1.00-1.06) 0.029 1.04 (1.01-1.08) 0.011 
SF-36 Physical Functioning$ 1.07 (0.90-1.28) 0.416 1.03 (0.81-1.32) 0.755 
SF-36 Physical role$ 1.09 (0.95-1.25) 0.201 0.92 (0.77-1.10) 0.401 
SF-36 Emotional role$ 1.16 (1.01-1.33) 0.026 1.04 (0.86-1.25) 0.665 
SF-36 Vitality$ 1.19 (1.02-1.39) 0.019 0.94 (0.77-1.15) 0.590 
SF-36 Mental Health$ 1.20 (1.04-1.39) 0.010 1.10 (0.90-1.33) 0.324 
SF-36 Social Functioning$ 1.20 (1.05-1.37) 0.005 1.00 (0.84-1.19) 0.955 
SF-36 Bodily Pain$ 1.13 (0.99-1.30) 0.066 1.04 (0.87-1.24) 0.619 
SF-36 General Health Perceptions$ 1.13 (0.98-1.31) 0.083 1.06 (0.88-1.29) 0.500 
SF-36 Physical component summary$ 1.00 (0.99-1.02) 0.361 0.99 (0.97-1.01) 0.824 
SF-36 Mental component summary$ 1.02 (1.00-1.03) 0.004 1.00 (0.98-1.02) 0.568 
IBDQ Bowel Symptoms score$ 1.01 (1.00-1.03) 0.012 1.00 (0.98-1.02) 0.462 
IBDQ Emotional Function score$ 1.03 (1.10-1.06) 0.003 1.01 (0.98-1.05) 0.264 
IBDQ Social Function score$ 1.01 (1.00-1.03) 0.001 1.00 (0.99-1.02) 0.323 
IBDQ Systemic Symptoms score$ 1.02 (1.00-1.05) 0.020 0.98 (0.95-1.01) 0.348 
IBDQ total score$ 1.00 (1.00-1.01) 0.002 1.00 (0.99-1.00) 0.523 
 
